{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:33:11Z","timestamp":1794670391512,"version":"4.9.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shanghai Clinical Research Center for Interventional Medicine","award":["19MC1910300"],"award-info":[{"award-number":["19MC1910300"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the standard of care after coronary stenting, including coronary stenting involving bioresorbable scaffolds (BRSs). Current clinical guidelines recommend at least 12\u00a0months of DAPT after BRS implantation. However, the correlation between prolonged DAPT and net clinical benefits remains unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The SPARTA trial is designed to be a prospective, randomized, parallel-group, clinical trial. It aims to compare the benefits and risks of DAPT applied for either 12 or 36\u00a0months after XINSORB BRS implantation. The primary endpoints are the incidence of the composite endpoint of major adverse cardiac events (MACEs), including all-cause death, any myocardial infarction (MI), and all revascularizations, as well as Bleeding Academic Research Consortium Definition (BARC) type 3 or 5 bleeding events. The secondary endpoints of the study include the device-oriented composite endpoint of target lesion failure (defined as cardiac death, target vessel-related MI, or ischemia-driven target lesion revascularization), target vessel failure (defined as cardiac death, MI, or ischemia-driven target vessel revascularization), scaffold thrombosis, and minor bleeding events. This trial will enroll 2106 subjects treated with the XINSORB BRS only. All subjects will receive DAPT after the index procedure for 12 (\u00b1\u20091) months. Subjects without MACEs or major bleeding will be randomized to receive either 24 additional months of DAPT or aspirin alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial is designed to investigate the impact of extending the duration of DAPT up to 3\u00a0years after XINSORB BRS implantation by investigating the balance of risks and benefits in a broad population of treated patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04501900?term=04501900&amp;recrs=ab&amp;draw=2&amp;rank=1\">NCT04501900<\/jats:ext-link>. Registered on 6 August 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-07028-8","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:06:49Z","timestamp":1674259609000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The standard versus prolonged dual antiplatelet therapy after the XINSORB bioresorbable scaffold implantation (SPARTA) trial: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-7969","authenticated-orcid":false,"given":"Yizhe","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"key":"7028_CR1","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4244\/EIJ-D-17-00873","volume":"13","author":"B Chevalier","year":"2018","unstructured":"Chevalier B, Cequier A, Dudek D, Haude M, Carrie D, Sabat\u00e9 M, et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention. 2018;13:1561\u20134.","journal-title":"EuroIntervention"},{"key":"7028_CR2","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","volume":"70","author":"DJ Kereiakes","year":"2017","unstructured":"Kereiakes DJ, Ellis SG, Metzger C, Caputo RP, Rizik DG, Teirstein PS, et al. 3-year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III Trial. J Am Coll Cardiol. 2017;70:2852\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"7028_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","volume":"137","author":"ZA Ali","year":"2018","unstructured":"Ali ZA, Gao R, Kimura T, Onuma Y, Kereiakes DJ, Ellis SG, et al. Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation. 2018;137:464\u201379.","journal-title":"Circulation"},{"key":"7028_CR4","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1001\/jamacardio.2019.4101","volume":"4","author":"GW Stone","year":"2019","unstructured":"Stone GW, Kimura T, Gao R, Kereiakes DJ, Ellis SG, Onuma Y, et al. Time-varying outcomes with the absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study. JAMA Cardiol. 2019;4:1261\u20139.","journal-title":"JAMA Cardiol"},{"key":"7028_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/eurheartj\/ehx488","volume":"39","author":"RA Byrne","year":"2018","unstructured":"Byrne RA, Stefanini GG, Capodanno D, Onuma Y, Baumbach A, Escaned J, et al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. Eur Heart J. 2018;39:1591\u2013601.","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"7028_CR6","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ccd.26404","volume":"87","author":"Y Wu","year":"2016","unstructured":"Wu Y, Shen L, Ge L, Wang Q, Qian J, Zhang F, et al. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery. Catheter Cardiovasc Interv. 2016;87(Suppl 1):630\u20137.","journal-title":"Catheter Cardiovasc Interv"},{"key":"7028_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijcard.2019.06.053","volume":"293","author":"Y Wu","year":"2019","unstructured":"Wu Y, Shen L, Yin J, Chen J, Qian J, Ge L, et al. Twelve-month angiographic and clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold and a metallic stent in patients with coronary artery disease. Int J Cardiol. 2019;293:61\u20136.","journal-title":"Int J Cardiol"},{"key":"7028_CR8","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.21037\/atm-20-5668","volume":"8","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yin J, Chen J, Yao Z, Qian J, Shen L, et al. Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study. Ann Transl Med. 2022;8:1162. https:\/\/doi.org\/10.21037\/atm-20-5668.","journal-title":"Ann Transl Med"},{"key":"7028_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.21037\/atm-20-6739","volume":"8","author":"Y Wu","year":"2020","unstructured":"Wu Y, Yao Z, Yin J, Chen J, Qian J, Shen L, et al. Three-year clinical outcomes of a sirolimus-eluting bioresorbable scaffold (XINSORB) and a metallic stent to treat coronary artery stenosis. Ann Transl Med. 2020;8:1489. https:\/\/doi.org\/10.21037\/atm-20-6739.","journal-title":"Ann Transl Med"},{"key":"7028_CR10","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jcin.2018.11.029","volume":"12","author":"Y Wu","year":"2019","unstructured":"Wu Y, Shen L, Yin J, Chen J, Ge L, Ge J. 5 years of serial intravascular imaging outcomes of XINSORB sirolimus-eluting bioresorbable vascular scaffold. JACC Cardiovasc Interv. 2019;12:602\u20133.","journal-title":"JACC Cardiovasc Interv"},{"key":"7028_CR11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015\u201326.","journal-title":"Circulation"},{"key":"7028_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","volume":"65","author":"M Gilard","year":"2015","unstructured":"Gilard M, Barragan P, Noryani AAL, Noor HA, Majwal T, Hovasse T, et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777\u201386.","journal-title":"J Am Coll Cardiol"},{"key":"7028_CR13","first-page":"365","volume":"37","author":"G Helft","year":"2016","unstructured":"Helft G, Steg PG, Le Feuvre C, Georges JL, Carrie D, Dreyfus X, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365\u201374.","journal-title":"Eur Heart J"},{"key":"7028_CR14","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0140-6736(14)62052-3","volume":"385","author":"S Elmariah","year":"2015","unstructured":"Elmariah S, Mauri L, Doros G, Galper BZ, O\u2019Neill KE, Steg PG, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015;385:792\u20138.","journal-title":"Lancet"},{"key":"7028_CR15","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"},{"key":"7028_CR16","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"7028_CR17","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","volume":"66","author":"R Gao","year":"2015","unstructured":"Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, et al. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66:2298\u2013309.","journal-title":"J Am Coll Cardiol"},{"key":"7028_CR18","doi-asserted-by":"publisher","first-page":"e554","DOI":"10.4244\/EIJ-D-17-00796","volume":"14","author":"B Xu","year":"2018","unstructured":"Xu B, Yang Y, Han Y, Huo Y, Wang L, Qi X, et al. Comparison of everolimus-eluting bioresorbable vascular scaffolds and metallic stents: three-year clinical outcomes from the ABSORB China randomised trial. EuroIntervention. 2018;14:e554\u201361.","journal-title":"EuroIntervention"},{"key":"7028_CR19","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/ccd.27880","volume":"92","author":"J Ge","year":"2018","unstructured":"Ge J. Bioresorbable vascular scaffold for the treatment of coronary in-stent restenosis: New dawn or frost on snow? Catheter Cardiovasc Interv. 2018;92:678\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"key":"7028_CR20","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","volume":"371","author":"JA Ormiston","year":"2008","unstructured":"Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899\u2013907.","journal-title":"Lancet"},{"key":"7028_CR21","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2017","unstructured":"Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carri\u00e9 D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2017;388:2479\u201391.","journal-title":"Lancet"},{"key":"7028_CR22","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","volume":"65","author":"G Giustino","year":"2015","unstructured":"Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015;65:1298\u2013310.","journal-title":"J Am Coll Cardiol"},{"key":"7028_CR23","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","volume":"321","author":"JY Hahn","year":"2019","unstructured":"Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321:2428\u201337.","journal-title":"JAMA"},{"key":"7028_CR24","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381:2032\u201342.","journal-title":"N Engl J Med"},{"key":"7028_CR25","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414\u201327.","journal-title":"JAMA"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-07028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-07028-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-07028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:12:22Z","timestamp":1674259942000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-07028-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7028"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-07028-8","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the EC of Zhongshan Hospital (Approval No. B2020-324R). Written, informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate\u00a0{24}"}},{"value":"Not applicable\u2014no identifying images or other personal or clinical details of participants are presented here or will be presented in reports of the trial results. Informed consent materials are available from the corresponding author upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication\u00a0{32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests\u00a0{28}"}}],"article-number":"49"}}